Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
Stopped Study B7601011 was terminated on 29 Jan 2018 due to lack of efficacy in moderate/advanced Parkinson's disease.
Conditions
Interventions
- DRUG: Placebo
- DRUG: PF-06649751
Sponsor
Pfizer